How data science and AI will redefine R&D and clinical innovation
Life sciences organizations are entering a new phase where scientific, technical, and regulatory forces are converging. As teams prepare for the next wave of transformation, 2026 is poised to bring meaningful shifts in how discovery, development, and clinical groups design studies, generate insights, and operationalize advanced analytics at scale.
Domino Data Lab and AstraZeneca have a forward-looking discussion on the emerging trends that will shape the year ahead and what leaders can do now to position their teams for impact across both AI and modern data science practices.
Why watch:
- Hear AstraZeneca’s perspective on the trends that will matter most for data science and AI across R&D, clinical development, and digital transformation in 2026
- Get practical guidance on how data science and IT teams can prepare for rising expectations around model governance, analytical rigor, and operational readiness
- Learn how peers are planning for 2026 and what capabilities in data management, scientific computing, and AI-enabled workflows will differentiate organizations entering the next stage of life sciences innovation
Featured Speakers
Tiffany Fabianac
Director - FAIRR Analytics, Oncology Data Science & AI
I started my career as a molecular neurobiologist focused on increasing insights into the molecular mechanisms controlling peripheral nerve development and drug discovery efforts toward the development of Neurofibromatosis Type 2 therapies. I went on to manage 2 cellular and molecular neuroscience laboratories where I led the research and development of in-vitro and in-vivo models used to better understand conditions such as Multiple Sclerosis, Diabetic Neuropathy, Neurofibromatosis, and Schwannomatosis. I followed a passion for coding and statistics into the world of bioinformatics consulting where I designed, developed, and implemented analytics and data science systems for several of the world's largest pharmaceutical and biotechnology research organizations. In parallel, I leverage my skillset in statistical modeling, machine learning & predictive analytics to design, build, and productionize AI models as an independent contributor.
James O'Keefe
Head, Development and Regulatory Data, Digital & Technology
James O’Keefe is a seasoned life sciences and IT leader at Takeda , recognized for his customer-first approach and ability to lead complex initiatives with clarity and care. With deep expertise across regulatory operations, clinical operations, and process optimization, he has successfully driven large-scale transformation and growth, including P&L ownership of a $20M business and sustained 35% year-over-year revenue growth. Known for building high-performing, outcome-driven teams, James brings a consultancy mindset and strong business acumen to advancing operational excellence and innovation across the life sciences ecosystem.
Chris McSpiritt
VP, Life Sciences Strategy
Chris McSpiritt is a Product Strategist and Business Architect with two decades of experience in life sciences technology. He began his career at an eClinical startup and has since held roles spanning project management, consulting, and product leadership. Today, Chris helps organizations align strategy with execution by shaping technology roadmaps, go-to-market plans, and AI-enabled solutions. He bridges customer needs with product innovation, guiding teams to modernize clinical research and achieve measurable impact. Passionate about the future of eClinical and AI, Chris brings clarity, creativity, and practical results to every engagement.